Paolo Tarantino: Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer
Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X:
“Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer (TNBC). In a biomarker analysis of TRAIN2, among 389 patients with stage II-III HER2+ BC receiving neoadjuvant chemotherapy and dual HER2 blockade, 13% had high TILs (≥60%) and experienced a 3-year iDFS of 100% (vs 92% if TILs <60%).”
Read further.
Source: Paolo Tarantino/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.